Preparing for the EU Health Technology Assessment: Key Insights from the Upcoming 2026 Webinar

By João L. Carapinha

January 5, 2026

The European Commission is organizing a webinar set for 15 January 2026 for health technology developers of medicinal products. The event provides guidance on EU Health Technology Assessment (HTA) Regulation prep, focused on Joint Clinical Assessments (JCAs) for certain medicinal products, with topics including dossier submissions, timelines, and EU HTA Coordination Group interactions. Practical sessions will cover regulatory processes, and registration stays open until mid-January 2026.

The EU HTA Regulation (EU) 2021/2282 is key, as endorsed by the European Parliament and Council, and it sets a voluntary framework that evolves to mandatory JCAs with goals including less duplication in HTA and boosting efficiency across 27 member states. See details on official EU Health Technology webpages.

Reference url

Recent Posts

Genotype ECG Prediction

By João L. Carapinha

February 17, 2026

Bridging Genotype ECG Prediction to Enhanced Cardiovascular Risk Assessment Genotype ECG prediction advancements, exemplified by the CapECG model, enable direct mapping of genetic data to electrocardiogram ...
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL Treatment
Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi®) with gemcitabine and oxaliplatin (Glofit-GemOx)...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
NICE Backs Pegzilarginase for Arginase Deficiency The National Institute for Health and Care Excellence (NICE) final draft guidance recommends pegzilarginase arginase deficiency treatment (Loargys, Immedica) as an option for people ...